IA
IMVT icon

IndexIQ Advisors’s Immunovant IMVT Stock Holding History

IndexIQ Advisors’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$393K Buy
+71,281
New +$444K 0.01% 800

Other funds holding IMVT

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

IndexIQ Advisors's IMVT Position: Q1 2022 in Review

IndexIQ Advisors opened a new position in Immunovant (IMVT) in Q1 2022: 71,281 shares worth $393K. The stake represents 0.01% of the portfolio and ranks #800 among its holdings.

112 funds tracked by Wall St. Rank hold IMVT as of Q1 2022.

  • IndexIQ Advisors held 71,281 shares of Immunovant worth $393K as of Q1 2022.
  • Immunovant was a new IndexIQ Advisors position in Q1 2022.
  • Immunovant made up 0.01% of IndexIQ Advisors's portfolio in Q1 2022, its #800 holding.
  • 112 funds tracked by Wall St. Rank held Immunovant as of Q1 2022.

Based on IndexIQ Advisors's 13F filing for Q1 2022, filed 6 May 2022.